Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (211) 211
life sciences & biomedicine (203) 203
humans (178) 178
cardiovascular system & cardiology (125) 125
male (112) 112
female (109) 109
cardiac & cardiovascular systems (98) 98
middle aged (95) 95
adult (75) 75
risk factors (70) 70
cholesterol (65) 65
peripheral vascular disease (63) 63
aged (62) 62
atherosclerosis (60) 60
hypercholesterolemia (56) 56
cardiovascular disease (53) 53
lipids (53) 53
mutation (52) 52
abridged index medicus (47) 47
cardiovascular (47) 47
genetic aspects (47) 47
lipoproteins (47) 47
cholesterol, ldl - blood (39) 39
statins (39) 39
cardiovascular diseases (37) 37
hyperlipoproteinemia type ii - genetics (37) 37
low density lipoproteins (36) 36
heterozygote (35) 35
cardiology and cardiovascular medicine (34) 34
genetics (34) 34
cholesterol, hdl - blood (33) 33
familial hypercholesterolemia (33) 33
phenotype (32) 32
pharmacology & pharmacy (30) 30
biochemistry & molecular biology (26) 26
treatment outcome (26) 26
young adult (26) 26
adolescent (23) 23
internal medicine (23) 23
animals (22) 22
endocrinology & metabolism (22) 22
low density lipoprotein (22) 22
biological and medical sciences (21) 21
care and treatment (21) 21
medical sciences (21) 21
hyperlipoproteinemia type ii - drug therapy (20) 20
biomarkers - blood (19) 19
epidemiology (19) 19
general & internal medicine (19) 19
medicine, general & internal (19) 19
pcsk9 (19) 19
triglycerides (19) 19
analysis (18) 18
cardiovascular diseases - prevention & control (18) 18
coronary heart disease (18) 18
hematology (18) 18
homozygote (18) 18
medical colleges (18) 18
prospective studies (18) 18
risk assessment (18) 18
triglycerides - blood (18) 18
case-control studies (17) 17
coronary artery disease (17) 17
genetic predisposition to disease (17) 17
hyperlipoproteinemia type ii - diagnosis (17) 17
medical research (17) 17
pedigree (17) 17
cardiology. vascular system (16) 16
double-blind method (16) 16
health aspects (16) 16
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (16) 16
anticholesteremic agents - therapeutic use (15) 15
medicine, experimental (15) 15
polymorphism, single nucleotide (15) 15
genotype (14) 14
medicin och hälsovetenskap (14) 14
nutritional and metabolic diseases (14) 14
proprotein convertase 9 (14) 14
research (14) 14
cardiovascular diseases - drug therapy (13) 13
cholesterol, hdl - metabolism (13) 13
clinical medicine (13) 13
diagnosis (13) 13
drug therapy (13) 13
genetic variation (13) 13
hyperlipoproteinemia type ii - blood (13) 13
medical and health sciences (13) 13
mice (13) 13
randomized controlled trials as topic (13) 13
receptors, ldl - genetics (13) 13
studies (13) 13
apolipoproteins (12) 12
cardiac and cardiovascular systems (12) 12
cardiology (12) 12
cardiovascular diseases - epidemiology (12) 12
child (12) 12
clinical trials (12) 12
kardiologi (12) 12
phosphatidylcholine-sterol o-acyltransferase - genetics (12) 12
physiological aspects (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text HDL and cardiovascular disease
by Rader, Daniel J, Prof and Hovingh, G Kees, MD
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9943, pp. 618 - 625
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiovascular Diseases - etiology | Animals | Cardiovascular Diseases - metabolism | Risk Assessment | Cholesterol, HDL - metabolism | Cardiovascular Diseases - prevention & control | Humans | Risk Factors | Hypercholesterolemia - complications | Hypolipidemic Agents - pharmacology | Hypercholesterolemia - drug therapy | Hypercholesterolemia - metabolism | Physiological aspects | Genetic aspects | Research | Cardiovascular diseases | Cholesterol, HDL | Risk factors | Medical colleges | Coronary heart disease | Atherosclerosis | Cardiovascular disease | Lipids | Heart attacks | Cholesterol | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
by Raal, Frederick J, Prof and Honarpour, Narimon, MD and Blom, Dirk J, MD and Hovingh, G Kees, MD and Xu, Feng, MS and Scott, Rob, MD and Wasserman, Scott M, MD and Stein, Evan A, Prof and for the TESLA Investigators and TESLA Investigators
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9965, pp. 341 - 350
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Proprotein Convertases - antagonists & inhibitors | Double-Blind Method | Hyperlipoproteinemia Type II - blood | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Cholesterol, LDL - drug effects | Male | Treatment Outcome | Anticholesteremic Agents - adverse effects | Young Adult | Homozygote | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Injections, Subcutaneous | Adolescent | Cholesterol, LDL - metabolism | Adult | Female | Hyperlipoproteinemia Type II - drug therapy | Serine Endopeptidases | Hyperlipoproteinemia Type II - genetics | Proprotein Convertase 9 | Hypercholesterolemia | Low density lipoproteins | Atherosclerosis | Clinical trials | Monoclonal antibodies | Carbohydrate metabolism | Genetic aspects | Trans fatty acids | Mutation | Low density lipoprotein | Cholesterol | Statins | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
by Stroes, Erik S and Thompson, Paul D and Corsini, Alberto and Vladutiu, Georgirene D and Raal, Frederick J and Ray, Kausik K and Roden, Michael and Stein, Evan and Tokgözoğlu, Lale and Nordestgaard, Børge G and Bruckert, Eric and de Backer, Guy and Krauss, Ronald M and Laufs, Ulrich and Santos, Raul D and Hegele, Robert A and Hovingh, G. Kees and Leiter, Lawrence A and Mach, Francois and März, Winfried and Newman, Connie B and Wiklund, Olov and Jacobson, Terry A and Catapano, Alberico L and Chapman, M. John and Ginsberg, Henry N and European Atherosclerosis Society and European Atherosclerosis Society Consensus Panel
European heart journal, ISSN 0195-668X, 2015, Volume 36, Issue 17, pp. 1012 - 1022
no | Musclesymptoms | Mitochondrial | Lipids | Myalgia | Statin | Cholesterol | Consensus statement | Myopathy | Statin intolerance | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cholesterol Ester Transfer Proteins - antagonists & inhibitors | Proprotein Convertases - antagonists & inhibitors | Mitochondria, Muscle | Humans | Risk Factors | Consensus | Muscular Diseases - diagnosis | Genetic Predisposition to Disease - etiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Mitochondrial Diseases - complications | Complementary Therapies | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Diet | Creatine Kinase - metabolism | Hypolipidemic Agents - therapeutic use | Muscular Diseases - chemically induced | Serine Endopeptidases | Muscular Diseases - therapy | Proprotein Convertase 9 | Index Medicus | Review | Muscle symptoms
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus
by Besseling, Joost and Kastelein, John J. P and Defesche, Joep C and Hutten, Barbara A and Hovingh, G. Kees
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2015, Volume 313, Issue 10, pp. 1029 - 1036
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hyperlipoproteinemia Type II - complications | Receptors, LDL - genetics | Prevalence | Cross-Sectional Studies | Humans | Middle Aged | Netherlands - epidemiology | Logistic Models | Male | Diabetes Mellitus, Type 2 - epidemiology | Hyperlipoproteinemia Type II - metabolism | Insulin-Secreting Cells - metabolism | Confounding Factors (Epidemiology) | Cholesterol, LDL - metabolism | Adult | Female | Registries | Mutation | Diabetes Mellitus, Type 2 - complications | Hyperlipoproteinemia Type II - genetics | Low density lipoprotein | Metabolic disorders | Diabetes
Journal Article
Details down arrow
5. Full Text Multilevel omics: A next step on the way to understanding pulmonary arterial hypertension?
by Aman, Jurjan and Hovingh, G. Kees
Thorax, ISSN 0040-6376, 04/2019, Volume 74, Issue 4, pp. 317 - 318
primary pulmonary hypertension | Life Sciences & Biomedicine | Respiratory System | Science & Technology | Plasma | Familial Primary Pulmonary Hypertension | Hypertension, Pulmonary | Humans | Pulmonary Arterial Hypertension | Studies | Proteins | Lipoproteins | Mortality | Cardiovascular disease | Thromboembolism | Pulmonary hypertension | Cholesterol | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
by Raal, Frederick J, Prof and Stein, Evan A, Prof and Dufour, Robert, MD and Turner, Traci, MD and Civeira, Fernando, MD and Burgess, Lesley, Prof and Langslet, Gisle, MD and Scott, Russell, Prof and Olsson, Anders G, Prof and Sullivan, David, MD and Hovingh, G Kees, MD and Cariou, Bertrand, MD and Gouni-Berthold, Ioanna, MD and Somaratne, Ransi, MD and Bridges, Ian, MSc and Scott, Rob, MD and Wasserman, Scott M, MD and Gaudet, Daniel, Prof and for the RUTHERFORD-2 Investigators and RUTHERFORD-2 Investigators
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9965, pp. 331 - 340
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Proprotein Convertases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | Hyperlipoproteinemia Type II - blood | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Cholesterol, LDL - drug effects | Male | Treatment Outcome | Anticholesteremic Agents - adverse effects | Young Adult | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Injections, Subcutaneous | Adolescent | Cholesterol, LDL - metabolism | Adult | Female | Heterozygote | Hyperlipoproteinemia Type II - drug therapy | Serine Endopeptidases | Hyperlipoproteinemia Type II - genetics | Proprotein Convertase 9 | Hypercholesterolemia | Low density lipoproteins | Atherosclerosis | Clinical trials | Carbohydrate metabolism | Genetic aspects | Trans fatty acids | Statins | Mortality | Cardiovascular disease | Lipids | Mutation | Low density lipoprotein | Drug dosages | Cholesterol | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
by Kastelein, John J. P and Ginsberg, Henry N and Langslet, Gisle and Hovingh, G. Kees and Ceska, Richard and Dufour, Robert and Blom, Dirk and Civeira, Fernando and Krempf, Michel and Lorenzato, Christelle and Zhao, Jian and Pordy, Robert and Baccara-Dinet, Marie T and Gipe, Daniel A and Geiger, Mary Jane and Farnier, Michel
European heart journal, ISSN 0195-668X, 2015, Volume 36, Issue 43, pp. 2996 - 3003
Alirocumab † PCSK9 † Heterozygous familial hypercholesterolaemia † Cardiovascular risk † LDL-C | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Double-Blind Method | Drug Administration Schedule | Hyperlipoproteinemia Type II - blood | Humans | Middle Aged | Risk Factors | Antibodies, Monoclonal - adverse effects | Male | Treatment Outcome | Anticholesteremic Agents - adverse effects | Dose-Response Relationship, Drug | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Cholesterol, LDL - metabolism | Female | Heterozygote | Hyperlipoproteinemia Type II - drug therapy | Index Medicus | Life Sciences | Food and Nutrition | Santé publique et épidémiologie | Track Esc Clinical Trial Update | PCSK9 | Heterozygous familial hypercholesterolaemia | Alirocumab | LDL-C | Cardiovascular risk
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
by Hovingh, G Kees, Dr and Kastelein, John J P, Prof and van Deventer, Sander J H, Prof and Round, Patrick and Ford, John and Saleheen, Danish and Rader, Daniel J, Prof and Brewer, H Bryan, Prof and Barter, Philip J, Prof
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 452 - 460
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cholesterol Ester Transfer Proteins - antagonists & inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Humans | Middle Aged | Male | Fluorobenzenes - administration & dosage | Quinolines - administration & dosage | Quinolines - pharmacology | Young Adult | Netherlands | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Cholesterol, LDL - blood | Female | Dyslipidemias - drug therapy | Double-Blind Method | Cholesterol, HDL - drug effects | Pyrimidines - administration & dosage | Rosuvastatin Calcium | Cholesterol, LDL - drug effects | Treatment Outcome | Atorvastatin Calcium | Adolescent | Cholesterol, HDL - blood | Denmark | Aged | Sulfonamides - administration & dosage | Clinical trials | Cholesterol | Proteins | Studies | Lipids | Low density lipoprotein | Drug dosages | Statins | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The PCSK9 decade
by Lambert, Gilles and Sjouke, Barbara and Choque, Benjamin and Kastelein, John J. P and Hovingh, G. Kees
Journal of lipid research, ISSN 0022-2275, 2012, Volume 53, Issue 12, pp. 2515 - 2524
Antibodies | Low density lipoprotein metabolism | Proprotein convertase subtilisin/kexin type 9 | Drug therapy | Lipoprotein receptors | Cholesterol | Life Sciences & Biomedicine | Biochemistry & Molecular Biology | Science & Technology | Proprotein Convertases - antagonists & inhibitors | Dyslipidemias - drug therapy | Cardiovascular Diseases - drug therapy | Humans | Proprotein Convertases - metabolism | Cholesterol - metabolism | Proprotein Convertases - genetics | Phenotype | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Serine Endopeptidases - genetics | Serine Endopeptidases - metabolism | Anticholesteremic Agents - pharmacology | Proprotein Convertase 9 | Index Medicus
Journal Article
Details down arrow
Digital rights